Drug Price Trends for FINZALA

Average Pharmacy Cost for FINZALA

These are average pharmacy acquisition costs (net of discounts) from a US national survey

Drug Name	NDC	Price/Unit ($)	Unit	Date
FINZALA 1-0.02(24)-75 CHEW TAB	00093-8210-62	0.32362	EACH	2024-12-18
FINZALA 1-0.02(24)-75 CHEW TAB	00093-8210-28	0.32362	EACH	2024-12-18
FINZALA 1-0.02(24)-75 CHEW TAB	00093-8210-28	0.22701	EACH	2024-11-20

Market Analysis and Price Projections for Finzala

Introduction

Finzala, a combination oral contraceptive containing norethindrone acetate, ethinyl estradiol, and ferrous fumarate, is indicated for use by females of reproductive potential to prevent pregnancy. Here, we will delve into the market analysis and price projections for this medication.

Market Overview

The contraceptive market is highly competitive and diverse, with various types of products including oral contraceptives, intrauterine devices (IUDs), patches, and injectables. Finzala, as a combination oral contraceptive, competes within the oral contraceptive segment.

Target Market

Finzala is targeted at females of reproductive potential who are seeking a reliable and convenient method of contraception. The efficacy of Finzala has been established, but its use is contraindicated in certain populations, such as women with acute viral hepatitis, severe cirrhosis, or benign and malignant liver tumors[1].

Competitive Landscape

The oral contraceptive market is dominated by several key players, including pharmaceutical companies that offer a range of contraceptive products. Finzala competes with other combination oral contraceptives that may have similar formulations or different dosing regimens. The competitive landscape is influenced by factors such as efficacy, safety profile, patient compliance, and cost.

Pricing Strategy

The pricing of Finzala is influenced by several factors, including production costs, market demand, competition, and regulatory approvals. Here are some key points to consider:

Production Costs

The cost of producing Finzala includes the cost of the active ingredients (norethindrone acetate and ethinyl estradiol), the non-hormonal placebo component (ferrous fumarate), and the manufacturing process. These costs can fluctuate based on raw material prices and manufacturing efficiencies.

Market Demand

The demand for oral contraceptives is relatively stable, driven by the ongoing need for effective contraception. However, market demand can be affected by factors such as changes in healthcare policies, insurance coverage, and patient preferences.

Competition

The pricing of Finzala must be competitive with other oral contraceptives on the market. Pharmaceutical companies often engage in price competition to gain market share, but they must also ensure that the pricing is sustainable and profitable.

Regulatory Approvals and Patents

Finzala's pricing can be influenced by its patent status and regulatory approvals. Since Finzala is a well-established product with initial U.S. approval in 1968, it is likely that generic versions may be available, which could impact pricing[1].

Price Projections

Given the competitive nature of the market and the established presence of Finzala, here are some considerations for price projections:

Current Pricing

As of the latest data, the exact retail price of Finzala is not publicly disclosed in the sources provided. However, it is generally priced in line with other combination oral contraceptives.

Future Trends

• Generic Competition: The presence of generic versions could lead to downward pressure on prices.
• Market Demand: Stable demand for oral contraceptives suggests that prices may remain relatively stable unless there are significant changes in the market or regulatory environment.
• Inflation and Economic Factors: General inflation and economic conditions can influence the pricing of pharmaceutical products.

Financial Performance of Similar Products

While Finzala itself is not discussed in terms of financial performance in the provided sources, the financial performance of other pharmaceutical products can provide some insights. For example, UCB's financial updates indicate strong revenue growth driven by their key products, but this does not directly relate to Finzala[2][4].

Regulatory and Safety Considerations

Regulatory and safety considerations play a crucial role in the pricing and market positioning of Finzala. The product has specific contraindications and warnings, such as the risk of serious cardiovascular events and liver disease, which must be factored into its market strategy[1].

Patient Compliance and Counseling

Patient compliance is a significant factor in the success of any contraceptive. Finzala's packaging and dosing regimen are designed to enhance compliance, with 24 active tablets and 4 non-hormonal placebo tablets. Effective patient counseling can also impact the product's market performance and pricing strategy.

Key Takeaways

• Market Positioning: Finzala competes in a crowded oral contraceptive market with a well-established formulation.
• Pricing Factors: Production costs, market demand, competition, and regulatory approvals influence pricing.
• Future Trends: Generic competition and market demand stability are key factors in price projections.
• Regulatory Considerations: Safety warnings and contraindications must be considered in market strategy.

FAQs

1. What is Finzala used for?

   • Finzala is used by females of reproductive potential to prevent pregnancy.

2. What are the active ingredients in Finzala?

   • The active ingredients are norethindrone acetate and ethinyl estradiol.

3. How is Finzala administered?

   • One tablet is taken daily, chewed and swallowed or swallowed whole, at the same time every day for 28 days.

4. What are the contraindications for Finzala?

   • Finzala is contraindicated in women with acute viral hepatitis, severe cirrhosis, or benign and malignant liver tumors.

5. Can Finzala be used by women with a high BMI?

   • The efficacy of Finzala in females with a body mass index (BMI) of more than 35 kg/m² has not been evaluated.

Cited Sources

1. Drugs.com: Finzala: Package Insert / Prescribing Information.
2. UCB: UCB's financial update.
3. FDA: 212102Orig1s000 - accessdata.fda.gov.
4. PR Newswire: UCB on Growth Path for a Decade Plus.